In glioma, using KIF11 inhibitors significantly inhibits the expression of four types of matrix metalloproteinases (MMPs), including MMP-1/2/3/9, causing extracellular matrix turnover and cancer cell migration [126,170]. The gene discussed is KIF11; the disease is central nervous system cancer.